Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.1 million.

  • Zevra Therapeutics' Interest Expenses fell 1128.89% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 3906.65%. This contributed to the annual value of $7.4 million for FY2024, which is 38974.02% up from last year.
  • Per Zevra Therapeutics' latest filing, its Interest Expenses stood at $2.1 million for Q3 2025, which was down 1128.89% from $2.0 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Interest Expenses high stood at $2.3 million for Q3 2024, and its period low was $5000.0 during Q4 2021.
  • For the 5-year period, Zevra Therapeutics' Interest Expenses averaged around $812736.8, with its median value being $199000.0 (2021).
  • Per our database at Business Quant, Zevra Therapeutics' Interest Expenses tumbled by 9957.08% in 2021 and then soared by 354000.0% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Interest Expenses stood at $5000.0 in 2021, then soared by 3300.0% to $170000.0 in 2022, then surged by 344.71% to $756000.0 in 2023, then surged by 190.21% to $2.2 million in 2024, then fell by 6.52% to $2.1 million in 2025.
  • Its Interest Expenses was $2.1 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.0 million in Q1 2025.